Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA: KRd vs. VRd in Newly Diagnosed Multiple Myeloma
NCT03729804Phase 3Active, not recruiting
- Sponsor
- University of Chicago
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by University of Chicago. Started May 2019; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03729804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729804.